Key result
RBP4 knockdown reduces post-AMI infarct size and cardiac dysfunction by attenuating NLRP3-mediated pyroptosis.
Why the study?
The mechanisms underlying activation of cardiomyocyte pyroptosis during acute myocardial infarction are not fully elucidated.
Does RBP4 modulation affect cardiomyocyte pyroptosis and cardiac injury in AMI models?
Does RBP4 modulation affect cardiomyocyte pyroptosis and cardiac injury in AMI models?
RBP4 promotes cardiomyocyte pyroptosis via direct interaction with NLRP3 in AMI, identifying it as a potential therapeutic target to prevent cardiac injury.
RBP4 inhibition attenuates murine AMI injury; leaves open whether targeting pyroptosis improves human outcomes.
Background Acute myocardial infarction (AMI) is one of the leading causes of cardiovascular morbidity and mortality worldwide. Pyroptosis is a form of inflammatory cell death that plays a major role in the development and progression of cardiac injury in AMI. However, the underlying mechanisms for the activation of pyroptosis during AMI are not fully elucidated. Methods and Results Here we show that RBP4 (retinol-binding protein 4), a previous identified proinflammatory adipokine, was increased both in the myocardium of left anterior descending artery ligation-induced AMI mouse model and in ischemia-hypoxia‒induced cardiomyocyte injury model. The upregulated RBP4 may contribute to the activation of cardiomyocyte pyroptosis in AMI because overexpression of RBP4 activated NLRP3 (nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3) inflammasome, promoted the precursor cleavage of Caspase-1, and subsequently induced GSDMD (gasdermin-D)-dependent pyroptosis. In contrast, knockdown of RBP4 alleviated ischemia-hypoxia‒induced activation of NLRP3 inflammasome signaling and pyroptosis in cardiomyocytes. Mechanistically, coimmunoprecipitation assay showed that RBP4 interacted directly with NLRP3 in cardiomyocyte, while genetic knockdown or pharmacological inhibition of NLRP3 attenuated RBP4-induced pyroptosis in cardiomyocytes. Finally, knockdown of RBP4 in heart decreased infarct size and protected against AMI-induced pyroptosis and cardiac dysfunction in mice. Conclusions Taken together, these findings reveal RBP4 as a novel modulator promoting cardiomyocyte pyroptosis via interaction with NLRP3 in AMI. Therefore, targeting cardiac RBP4 might represent a viable strategy for the prevention of cardiac injury in patients with AMI.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied Acute myocardial infarction. RBP4 knockdown vs. Control was evaluated on Cardiomyocyte pyroptosis, infarct size, and cardiac dysfunction. Knockdown of RBP4 decreased infarct size and protected against AMI-induced pyroptosis and cardiac dysfunction in mice by attenuating NLRP3 inflammasome signaling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: